HilleVax, Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| HilleVax, Inc. | HLVX - NASDAQ |
$16.00-$18.00 | $17.00 | $18.76 | 11.8 million | 4/29/2022 |
| J.P. Morgan, SVB Leerink, Stifel, Guggenheim Securites | ||||||
Co-Manager(s): | ||||||
| Health Care | ||||||
Filing(s): Filed 2022-04-06 Terms Added 2022-04-25 | ||||||
HilleVax, Inc. Quote & Chart - Click for current quote - HLVX
IPO Boutique aggregates information on public companies and private companies, such as "HLVX" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About HilleVax, Inc. (adapted from HilleVax, Inc. prospectus):
They are a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines. Our initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines. Our initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "HLVX" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.